Reuters logo
BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise
October 20, 2017 / 12:15 PM / a month ago

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

* Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES

* Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below